作者
Luca Ponzone,Valentina Audrito,Claudia Landi,Enrico Moiso,Chiara Levra Levron,Sara Ferrua,Aurora Savino,Nicoletta Vitale,Massimiliano Gasparrini,Lidia Avalle,Lorenza Vantaggiato,Enxhi Shaba,Beatrice Tassone,Stefania Saoncella,Francesca Orso,Daniele Viavattene,Eleonora Marina,Irene Fiorilla,Giulia Burrone,Youssef Abili,Fiorella Altruda,Luca Bini,Silvia Deaglio,Paola Defilippi,Alessio Menga,Valeria Poli,Paolo E. Porporato,Paolo Provero,Nadia Raffaelli,Chiara Riganti,Daniela Taverna,Federica Cavallo,Enzo Calautti
摘要
The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the presence of the essential RICTOR subunit, regarded as an oncogenic driver in several tumor types, including MM.
劲秉
Polymer72
爱静静
无名老大
chen
maox1aoxin
子车茗
nku_xjli
mhl11
哎呀呀的小胖胖
pluto
七院
tuanheqi
模糊中正
夕阳兰草
无敌反派大美人
方羽
T9的梦
kingwill
Yifan2024
皖公网安备34019202002308
